(9H-Fluoren-9-yl)methyl piperazine-1-carboxylate hydrobromide

Catalog No. :
ACOHUQ390
CAS No. :
352351-60-1
Molecular Formula :
C19H21BrN2O2
Molecular Weight :
389.29

IUPAC Name:(9H-fluoren-9-yl)methyl piperazine-1-carboxylate hydrobromide

(9H-Fluoren-9-yl)methyl piperazine-1-carboxylate hydrobromide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$84.00Login to see priceInquiryInquiry
1g97%$226.00Login to see priceInquiryInquiry
5g97%$842.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(9H-Fluoren-9-yl)methyl piperazine-1-carboxylate hydrobromide
IUPAC Name(9H-fluoren-9-yl)methyl piperazine-1-carboxylate hydrobromide
MDL No.MFCD01863046
Molecular FormulaC19H21BrN2O2
Molecular Weight389.29
SMILESO=C(N1CCNCC1)OCC2C3=CC=CC=C3C4=CC=CC=C24.[H]Br
InChI KeyVPDNTWXXSYNWOE-UHFFFAOYSA-N
Synonym1-FMOC-PIPERAZINE HYDROBROMIDE;1-Fmoc-piperazine hydrobromide >=98.0% (HPLC);(9H-Fluoren-9-yl)methyl piperazine-1-carboxylate hydrobromide;1-Piperazinecarboxylic acid, 9H-fluoren-9-ylmethyl ester, hydrobromide (1:1)
CAS No.352351-60-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACOHUQ390 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACOHUQ390 route product structure diagram
    ACOHUQ390352351-60-1
Inquiry

2. ACOHUQ390 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOHUQ390 route product structure diagram
    ACOHUQ390352351-60-1
Inquiry

Comments (0)